Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies

• Daniel Y. Heng,

  Affiliation Department of Medical Oncology, Tom Baker Cancer Center, Alberta Health Services Cancer Care, University of Calgary, Calgary, Canada

  ⨯
• James Signorovitch,

  Affiliation Analysis Group, Inc., Boston, Massacusetts, United States of America

  ⨯
• Elyse Swallow,

  Affiliation Analysis Group, Inc., Boston, Massacusetts, United States of America

  ⨯
• Nanxin Li,

  Affiliation Analysis Group, Inc., Boston, Massacusetts, United States of America

  ⨯
• Yichen Zhong,

  Affiliation Analysis Group, Inc., Boston, Massacusetts, United States of America

  ⨯
• Paige Qin,

  Affiliation Analysis Group, Inc., Boston, Massacusetts, United States of America

  ⨯
• Daisy Y. Zhuo,

  Affiliation Analysis Group, Inc., Boston, Massacusetts, United States of America

  ⨯
• Xufang Wang,

  Affiliation Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America

  ⨯
• Jinhee Park,

  Affiliation Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America

  ⨯
• Sotirios Stergiopoulos,

  Affiliation Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America

  ⨯
• Christian Kollmannsberger

  * E-mail: ckollmannsberger@bccancer.bc.ca

  Affiliation Department of Oncology, British Columbia Cancer Agency, Vancouver, Canada

  ⨯